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Abstract 
Background: The concept of precision medicine in cancer includes individual molecular studies to predict clinical 
outcomes. In the present N = 1 case we retrospectively have analysed lymphoma tissue by exome sequencing and 
global gene expression in a patient with unexpected long‑term remission following relaps. The goals were to pheno‑
type the diagnostic and relapsed lymphoma tissue and evaluate its pattern. Furthermore, to identify mutations avail‑
able for targeted therapy and expression of genes to predict specific drug effects by resistance gene signatures (REGS) 
for R‑CHOP as described at http://www.hemaclass.org. We expected that such a study could generate therapeutic 
information and a frame for future individual evaluation of molecular resistance detected at clinical relapse.
Case presentation: The patient was diagnosed with a transformed high‑grade non‑Hodgkin lymphoma stage 
III and treated with conventional R‑CHOP [rituximab (R), cyclophosphamide (C), doxorubicin (H), vincristine (O) 
and prednisone (P)]. Unfortunately, she suffered from severe toxicity but recovered during the following 6 months’ 
remission until biopsy‑verified relapse. The patient refused second‑line combination chemotherapy, but accepted 
3 months’ palliation with R and chlorambucil. Unexpectedly, she obtained continuous complete remission and is at 
present >9 years after primary diagnosis. Molecular studies and data evaluation by principal component analysis, 
mutation screening and copy number variations of the primary and relapsed tumor, identified a pattern of branched 
lymphoma evolution, most likely diverging from an in situ follicular lymphoma. Accordingly, the primary diagnosed 
transformed lymphoma was classified as a diffuse large B cell lymphoma (DLBCL) of the GCB/centrocytic subtype by 
“cell of origin BAGS” assignment and R sensitive and C, H, O and P resistant by “drug specific REGS” assignment. The 
relapsed DLBCL was classified as NC/memory subtype and R, C, H sensitive but O and P resistant.
Conclusions: Thorough analysis of the tumor DNA and RNA documented a branched evolution of the two clinical 
diagnosed tFL, most likely transformed from an unknown in situ lymphoma. Classification of the malignant tissue for 
drug‑specific resistance did not explain the unexpected long‑term remission and potential cure. However, it is tempt‑
ing to consider the anti‑CD20 immunotherapy as the curative intervention in the two independent tumors of this 
case.
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Background
Follicular lymphoma (FL) is a low-grade non-Hodgkin’s 
type lymphoma with a median survival of 8–10  years 
[1, 2]. It can evolve into the more aggressive histology of 
transformed FL (tFL) [3], resembling diffuse large B-cell 
lymphoma (DLBCL), but share a distinct gene expression 
profile and immunophenotype with the primary FL [4–
8]. This transformation occurs by the expansion of one or 
more subclones with loss of the follicular growth pattern 
resulting in a rapidly progressive clinical course refrac-
tory to treatment and with inferior prognosis. To distin-
guish between progression and transformation of FL a 
biopsy for histological examination is needed in case of 
symptoms and CT verified tumor progression. The his-
tological verified presence of both follicular and diffuse 
architecture in the initial diagnostic biopsy represents a 
finding that implies early transformation of FL [2, 3]. The 
survival post-transformation ranges between median 
7–20 months [9, 10].
Similar to progression, the transformation is a clonal 
evolution from an ancestral clone that initially arises 
from a common normal cell of origin (COO) through 
linear or branched outgrowth of an existing subclone, 
deregulated by random genetic or epigenetic hits.
Our knowledge of genetic aberrations in FL has dra-
matically increased over the last few years, and recent 
comprehensive studies by exome sequencing has identi-
fied the mutational landscape and the genetic changes 
that contribute to the step wise tumor progression, 
including transformation to DLBCL [4–8, 11–18].
Here we report a unique, biopsy and histology verified 
case of primary tFL with relapse and long-term remission 
following palliation therapy. As molecular studies of such 
unexpected outcome may be informative, we decided to 
study the two malignant tissue biopsies and a germ line 
DNA sample to thorough analysis with the aim to iden-
tify differences in an attempt to understand and explain 
the clinical outcome.
The case will also illustrate the molecular technologies, 
knowledge and competences that are increasingly avail-
able to challenge the “one size fits all” approach to early 
clinical phase I–II drug trials in relapsed patients and 
replace this with a predictive strategy. We envisage that 
therapies will be stratified to reflect disease heterogene-
ity, in a departure from the current use of non-precise 
chemotherapeutic agents and allow for the development 
of new taxonomy and companion diagnostics—a clear 
need in future clinical care.
Case presentation
Early August, 2007, a previously healthy 74  year-old 
woman was referred to the Department of Hematology 
at Aalborg University Hospital with a 3-month history 
of weight loss (5%) and abdominal pain. A computed 
tomography (CT) was performed as part of the initial 
diagnostic work-up and revealed a bulky retroperitoneal 
tumor measuring 13.5  ×  12  ×  7.5  cm. Pathologically 
enlarged lymph nodes were also detected in all supra- 
and infra-diaphragmatic stations and the spleen was 
enlarged (Additional file 1: Figure S1A, July, 2007). Fur-
thermore, she had bilateral hydronephrosis.
A tumor biopsy from an axillary lymph node was per-
formed. Morphological examinations revealed a picture 
typical for diffuse large B-cell lymphoma (DLBCL), but 
with nodular areas consistent with an underlying follicu-
lar lymphoma. The cells were monoclonal IgM+, kappa+, 
CD20+, CD19+, CD10+, CD38+, CD79A+, BCL2+ and 
BCL6+, CD30− with a high Ki67-estimated sproliferation 
rate. On the basis of these findings a diagnosis of DLBCL 
transformed from follicular lymphoma was made. The 
routine bone marrow biopsy and aspiration was clear for 
signs of lymphoma infiltration. The disease was catego-
rized as stage III according to the Ann Arbor classifica-
tion based on the extensive nodal involvement on both 
sides of the diaphragm.
A combined modality treatment with six cycles of 
R-CHOP (Rituximab, cyclophosphamide, doxorubicin 
(hydroxydaunomycin), vincristine (oncovin) and pred-
nisolon) followed by consolidating radiotherapy against 
the abdominal bulk tumor was planned. Unfortunately, 
her treatment was complicated by severe infectious epi-
sodes including septicemia. After the final R-CHOP 
cycle, she had lost an additional 10 kg and was in a clini-
cal poor performance status. An 18F-FDG positron emis-
sion tomography/CT (PET/CT) performed at this point 
showed a residual PET-negative tumor mass surrounding 
the aorta (Additional file 1: Figure S1B, January, 2008). As 
a result of her poor condition she entered post-therapy 
follow-up without receiving the planned radiotherapy.
A routine PET/CT study performed after three months 
of follow-up confirmed continues remission (Additional 
file 1: Figure S1C, March, 2008). However, a routine PET/
CT study performed 6 months into the follow-up period 
revealed clear progression of the retroperitoneal tumor 
in terms of increased size and FDG-uptake (SUVmax 11.2) 
(Additional file 1: Figure S1D, July, 2008). A tumor biopsy 
directed from an enlarged cervical lymph node revealed 
a morphological and immunohistochemical picture simi-
lar to that seen in the primary diagnostic biopsy (see 
above)—thus being consistent with relapse of DLBCL 
transformed from a follicular component.
In light of the severe complications during the primary 
R-CHOP therapy, she declined intensive chemotherapy 
and specifically asked for a palliative approach. She there-
fore received four doses of rituximab given every 3 weeks 
combined with continues oral chlorambucil (Leukeran®) 
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at a dose of 4  mg per day as maintenance. Chlorambu-
cil was stopped after 6 month due to side effects. At 
this point she was unwilling to accept any further lym-
phoma directed therapies or investigations but accepted 
clinical follow up including a PET/CT scan documenting 
remission.
Surprisingly, she slowly recovered and regained weight 
over the following months and a control PET/CT showed 
remission (Additional file  1: Figure S1E, July, 2010). At 
the last follow-up visit August 2016, 9 years after the ini-
tial diagnosis, she was still in good health without lym-
phoma-related symptoms or findings.
Method section
The aim, design and setting of the study
Based on the unexpected long-term remission of a 
tFL patient on palliative therapy for her first relapse, 
we obtained informed consent to perform a thorough 
molecular analysis on her primary and relapsed tumor. 
The idea was to explore den molecular background in 
her tumor samples in search for an explanation for her 
cure following palliation with rituximab (Mabthera®) and 
chlorambucil (Leukeran®).
Additional malignant tissue were available and 
included, from NHL patients at time of diagnosis before 
treatment and diagnosis were evaluated according to the 
Revised European-American Lymphoma Classification 
[1] and confirmed by two expert hematopathologists at 
Aalborg University Hospital. Included were patients who 
had tissue stored in the “Diagnostic Biobank, Depart-
ment of Hematology, Aalborg” and clinical data, staging, 
therapy and outcome registered in the National Clinical 
Quality Database for lymphoma, as approved by the local 
ethical committee (RetroGene, N-20140099).
Gene expression profiling (GEP)
RNA from 50 lymphoma samples FL (n = 7), tFL (n = 2; 
the case) and DLBCL (n = 41) was purified, labeled and 
hybridized to Affymetrix GeneChip Human Genome 
U133 Plus 2.0 Arrays and.CEL files generated as 
described [18] and presented in Additional file  2: Table 
S1. All were diagnostic samples taken before initiation 
of treatment. The relapse tFL sample (H385) being the 
exception, as the patients received R-CHOP treatment 
for her primary tumor (H302).
Resistance gene signatures (REGS) for drug response
The effect of the drugs cyclophosphamide (C), doxoru-
bicin (H), vincristine (O) and rituximab (R) on viable pro-
liferating B-cell lines was measured by an in  vitro drug 
screen strategy as recently described by our group [19–
24]. Sensitivity or resistance towards individual drugs 
can be predicted by the REGS assignment of probability, 
which ranges from zero to one, respectively. A website 
(http://www.hemaClass.org) [25] has been generated to 
grant access to the classification and prediction tools to 
all researchers by easy upload of .CEL-file data. The.CEL 
files from the patient case tumors were analyzed and as 
build-in reference, our collection of lymphoma samples 
(RetroGene) performed at our laboratory was chosen in 
the RMA pre-processing normalization step. We chose 
the following classification systems: BAGS, R, C, H, O, 
P and R-CHOP, with the following ranges of non classi-
fied/intermediate groups: 0.1–0.9; 0.38–0.54; 0.33–0.55; 
0.14–0.9; 0.46–0.62; 0.09–0.93, respectively. The results 
are downloaded and displayed in Table 3.
DNA purification
DNA from the patient’s two tumor samples was purified 
as described [26]. The patient’s saliva sample was col-
lected using the Oragene DNA Self-Collection Kit (OG-
500) and the DNA purified from non-involved mucosa 
cells using the Oragene DNA purifier (OG-L2P) follow-
ing manufactures instructions in protocol PD-PR-006 
Issue 3.2 (DNA Genotek Inc, Ottawa, Ontario, Canada).
Global copy number variation (CNV)
The purified DNA was labeled and hybridized to Affy-
metrix SNP6 arrays as described [26]. The .CEL files, 
generated through AGCC after scanning the arrays, 
were imported to Partek Genomics Suite Software v. 
6.6 (6.14.0828) using interrogating probes only with a 
pre-background adjustment for GC content and probe 
sequence. Probe sets wire summarized using allele spe-
cific summarization, and normalized against the human 
Hapmap genome. Amplification and deletions were 
detected through genomic copy number segmentation 
using standard settings, in brief: minimum 10 genomic 
markers, a P value threshold of 0.001, and a signal to 
noise ratio of 0.3. The diploid copy number range was set 
to 1.7–2.3.
Exome sequencing and analysis
From the patient’s saliva, primary and relapse tumor 
samples, standard sequence libraries for studies of point 
mutations were created from 100 ng of DNA from each 
sample, following exome capture using the Agilent Sure-
Select Human All Exon 50  Mb system (Agilent Tech-
nologies). Sequencing was performed on a HighSeq 2000 
(Illumina, Hinxton, UK) using 76-bp paired-end reads, as 
described [27, 28].
Raw reads from the sequencer were processed follow-
ing the Genome Analysis Toolkit (GATK) best practice 
guidelines [29, 30]. Reads were aligned to the grch37 
assembly of the human genome with BWA v0.7.12 [31]. 
Aligned reads were sorted, converted to BAM format and 
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had PCR duplicates marked using Picard v2.0.1 (http://
broadinstitute.github.io/picard/). Sequence realignment 
around INDELs and adjustment of quality scores was 
done using GATK v.3.5.0 [32]. Discovery of somatic vari-
ants in both primary and relapse tumors was performed 
using MuTect2 [33] incorporating information from 
dbSNP v138 [34] and COSMICv75 [35]. Somatic variants 
that passed quality filters were annotated using Oncota-
tor v.1.8.0.0 [36] and finally PHIAL v1.0 [37] was used to 
score and rank somatic mutations according to clinical 
relevance and to identify potential targeted therapy for 
the analyzed patient.
Datasets
The micro array data are deposited at Gene Expression 
Omnibus in project GSE86622, see Additional file  2: 
Table S1. The exome sequencing data from the tFL 
patient samples: non-involved mucosa cells, the lym-
phoma diagnostic sample and the sample following clini-
cal relaps, are available through the European Genome 
Phenomena Archive at the European Bioinformatics 
Institute under accession number EGAD00001002707.
Statistical analysis
All statistical analyses were performed using R (The R 
Development Core Team, 2013) version 3.0.1 [38–41].
Results
In the present N = 1 case we have analysed the diagnostic 
and relapsed lymphoma tissue DNA and RNA by exome 
sequencing and microarray expression respectively. The 
primary goal was to phenotype the lymphoma tissues and 
evaluates its evolution pattern. The secondary goals were 
in a therapeutic context to identify specific mutations 
available for targeted therapy and expression of genes to 
predict specific drug effects of R-CHOP. It is expected 
that we could generate information useful in this specific 
and unexpected case.
Principal component analysis of DLBCL, FL and the case 
samples
The gene expression profiles of the primary and relapse 
samples from our patient case were analyzed together with 
7 FL and 41 DLBCL cases from our clinic in a principal 
component analysis (PCA) with the results as illustrated 
in Fig. 1. The cases formed two distinct groups, where the 
diagnostic and relapse tFL samples were different, in close 
proximity to the FL and DLBCL groups, respectively.
Mutation identification by exome sequencing of the case 
samples
We performed exome sequencing on the primary and 
the relapse tumor and identified somatic changes in 
687 SNPs and INDELs compared to the constitutional 
DNA obtained from the patient’s saliva. The primary 
(H302) and relapse (H385) tumors contained 329 and 
358 somatic tumor specific changes, respectively, with 
an overlap of 127, as shown in Table  1. A thorough 
review of clinically relevant mutated genes, two (EZH2 
and DNMT3A) were unique for the primary tumor and 
two were unique for the relapse tumor (FBXW7 and 
FIP1L1). Three of the genes were found in both tumors 
(NOTCH2, TP53 and EP300), however, NOTCH2 were 
present at different allelic fractions in the two tumors 
(Table 2). Of the 37 recurrent gene mutations described 
by Pasqualucci [8] we recognized mutations in BCL2, 
HIST1H1E, EP300, TP53 and STAT6 in both tumors, 
EZH2 in the primary and KDM6B in the relapsed tis-
sue. Overall, the mutation pattern recognized suggests a 
branched evolution from an unknown common mutated 
ancestor through the independent acquisition of distinct 
genetic lesions.
This was also visualized by global SNP6-microarray 
analysis for copy number variations (CNV) above 100 kb 
as illustrated in Fig. 2. The diagnostic and relapse samples 
had various chromosomal regions with identical CNV, 
illustrated for chromosomes 1, 6, 9, 16, 17 and X. How-
ever, many CNVs were unique to the primary tumor—
see chromosomes 3, 4, 7, 10, 17 and X, or unique to the 
relapsed tissue seen in chromosomes 2, 3, 4, 5, 7, 8, 10, 
11, 12, 16, 18, 19.
In summary, the diagnostic and relapsed tFL har-
bor unique mutations and CNVs documenting that the 
tumors have a common genetic background and the tFL 
case is a consequence of branched and not direct linear 
clonal selection and evolution.
Estimation of drug sensitivity for the case samples
The primary and relapse samples were assigned a cell of 
origin (COO) subtype as described [18] resistance esti-
mate for R-CHOP by REGS [19–21] classifiers follow-
ing assignment in http://www.hemaClass.org [25]. This 
tool provides an easy interface for one-by-one microar-
ray based classification based on our preclinical models 
for BAGS and REGS. By individual REGS assignment, 
the primary tumor was predicted to be resistant to the 
drugs C, H, O and P, but sensitive towards R. In contrast, 
the relapse tumor had changed drug sensitivity for the 
alkylating agents C but still resistant towards O and P 
as well as the very high sensitive towards R, as shown in 
Table 3.
In summary, the gene signature based subtyping of the 
two tFL tissue support that they were different although 
with important overlaps. From a functional perspective 
both tissues are R sensitive, indicating that the patient 
was cured by the targeted anti-CD20 therapy.
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Discussion
“N of 1” case studies require prospective collection of 
individual tissue into biobanks and storage of molecular 
data from standardized tissue analysis. Here we describe 
a unique patient who was “cured” for tFL and we pre-
sent data that identify the differential pattern of genetic 
evolution and furthermore classify the lymphomas by 
resistance estimates for the specific drugs in question.
The tFL presented in this case was advanced stage at 
diagnosis and a poor outcome was expected [9]. Even if 
such cases are rare, we believe that the knowledge from 
our work will be useful if we can collect and assemble 
such data across several cases [42]. In the era of precision 
medicine, the design of various types of medical “data 
commons” may allow us to compare individual cases. It is 
our hope that other research groups will perform similar 
extensive molecular analysis of tFL cases with long-term 
remission in order to improve understanding of patho-












































































Fig. 1 Principal component analysis (PCA) of the tFL case compared to FL and DLBCL samples. A principal component (PC) analysis on GEP from 7 
FL, 41 DLBCL samples and the patient’s primary and relapse tumors was performed. All probe sets for all samples were included in the PC analysis. a 
The two diagnostic entities, FL and DLBCL, segregated into distinct clusters in the PC analysis, with the primary and relapse tumor samples located 
at the edges of the FL and DLBCL groups, respectively. b The proportion of variance in the 10 first PC’s are displayed
Table 1 Classification of  variants in  primary and  relapsed 
tumor
Variant Primary Relapse Shared
3’UTR 4 10 4
5’Flank 1 1 0
5’UTR 2 2 1
Frame_Shift_Del 0 3 0
Frame_Shift_Ins 2 1 0
IGR 48 42 12
In_Frame_Del 0 3 0
Intron 109 124 42
lincRNA 4 8 2
Missense_Mutation 110 94 46
Nonsense_Mutation 3 6 2
RNA 18 20 8
Silent 23 37 7
Splice_Site 5 7 3
Total 329 358 127
Table 2 Clinically relevant variants detected by PHIAL
Coverage Allelic fraction
Gene Variant Primary Relapse Primary Relapse
TP53 Missense_Mutation 35 37 0.66 0.62
NOTCH2 Nonsense_Mutation 24 26 0.58 0.27
EP300 Missense_Mutation 55 63 0.31 0.33
DNMT3A Splice_Site 52 NA 0.08 NA
EZH2 Missense_Mutation 37 NA 0.3 NA
FBWX7 Missense_Mutation NA 64 NA 0.38
FIP1L1 Splice_Site NA 59 NA 0.37
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Documentation of lymphoma evolution
Sequencing the malignant genome has opened new 
knowledge to the complexity of malignant lymphoma 
cell genetics, selection and Darwinian evolution [43, 
44]. Multiple studies have analysed paired biopsies from 
indolent follicular lymphoma and its transformation for 
differential genetic aberrations associated to the clini-
cal progression. A common finding is the premalignant 
IGH-BCL2 hybrid transcript expression and several key 
genetic events that seem to drive the process of progres-
sion [5, 6, 8]. In parallel, comparative analysis can also 
identify the genotypic background and, as in our case, 
document patterns of branched or linear lymphoma evo-
lution. From published data, we have a long list of recur-
rent driver mutations from functional screening that 
illustrates the complexity and how heterogeneous the tFL 
genomes actually are.
In the present case, recurrent somatic mutations of 
BCL2, NOTCH2, TP53 and EP300 were identified in the 
primary and relapsed tumor, which indicates a common 
progenitor cell, most likely a transformation from an 
unknown in  situ or premalignant follicular lymphoma 
[45, 46]. The branched evolution was supported by the 
presence of gene mutations unique to the primary tFL 
tumour, e.g. the recurrent genes, EZH2 and DNMT3A 
that were mutated in 30 and 8% of the reads, but not 
mutated in the reads from the relapse tFL tumour. On the 
contrary the relapsed tumor had several specific muta-
tions e.g. in FBXW7 and FIP1L1.
In summary, the data (Figs. 1, 2 and Tables 1, 2) con-
firms that each of the individual tFL in our patient case 
has unique genomic profiling. The precision medicine 
concept argues that genetic heterogeneity is a key-factor 
for therapeutic failure. This limitation is broadly recog-
nized and represents a considerable challenge, techni-
cally and bioinformatically. Understanding the genetic 
diversity and how it changes in response to interventions, 
will require deep sequencing and analysis of the genomes 
of highly selected single cells [47, 48].
Impact of gene signature classification of COO and drug 
resistance
Despite the enormous resources spent on developing 
molecular based cancer classification systems, most of 
these are still not available in clinical practice. To allow 
implementation and fast validation of our recent findings 
in DLBCL [18–21], we have developed an easily acces-
sible web application that permits other users to assign 
ABC/GCB, B-cell associated gene signature (BAGS) as 
well as drug specific resistance gene signature (REGS) 
Fig. 2 Copy number analysis of diagnostic and relapsed tFL tissue. Copy number variations above 100 kb in all chromosomes are displayed for the 
saliva sample, the primary and the relapse tumors from the tFL patient case. The image was generated through Partek™ Genomics Suite Software
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on their own datasets. The website called hemaClass.
org [25] is a new prospect for easy individual subtyping 
of malignant B cell diseases; in particular for DLBCL and 
myeloma.
In summary, the primary diagnosed tFL was classi-
fied as a diffuse large B cell lymphoma (DLBCL) of the 
GCB/centrocytic subtype by “cell of origin BAGS” assign-
ment and R-CHOP resistant by “drug specific REGS” 
assignment. The relapsed DLBCL was classified as NC/
memory subtype and R-CHOP sensitive in support of the 
branched evolution. Monitoring such functional varia-
tions following treatment may identify the mechanisms 
of molecular drug resistance resulting in clinical relapse.
Limitations of the study
This case study may be important for future diagnostic 
phenotyping and implementation of individual targeted 
drug or specific predictive therapy, however it involves a 
range of clinical, biological, and statistical limitations to 
be considered.
First, we cannot trust the conventional classification 
of poor prognosis associated with tFL, to make a clini-
cal decision at the individual level. However, we expected 
this to be fulfilled by molecular profiling of drug spe-
cific sensitivity and resistance and mutations status for 
targeted therapy by designer drugs [49]. However, this 
strategy needs to be prospective validated by selected 
clinical end point, like level of remission, event free or 
overall survival. Such studies are ongoing, also in our 
center including all relapsed patients with haematologi-
cal malignancies, to be used in the future evidence based 
strategy for individualized targeted and predicted ther-
apy [49–53].
Second, the tissues analyzed are obtained from the 
biopsy of a single tumor focus, knowing that an entirely 
different profile might be seen from the biopsy of an adja-
cent lesion. The identification of the mutations within 
sub-clones is lost when DNA is extracted from the total 
cell population. This is most important if patient-and 
drug-specific genomic profiles are used for selecting 
therapeutic targets. This limitation represents a consider-
able challenge, technically and bioinformatically and will 
require deep sequencing and analysis of the genomes of 
single cells sorted by multiparametric flow cytometry.
Third, this case study has described a frame for future 
individual evaluation of clinical resistance detected at 
relapse. However, the individual REGS assignments given 
in Table 3 showed that the two tFL biopsies are R sensi-
tive and indicate a clinical response to targeted anti-CD20 
therapy for both tissues. However, we did not have a drug 
specific REGS predictor for the alkylating drug Chloram-
bucil, but the shift in sensitivity for the alkylating drug C 
may illustrate a potential sensitivity also to Chlorambucil 
therapy and a clinical impact in combination with R [54, 
55]. Ongoing preclinical drug screens do include clinical 
available drugs and clinical relevant combinations.
Fourth, it has to be stressed that the clinical impact of 
REGS assignment is documented by retrospective anal-
ysis of thousands of patient sample data from several 
international clinical drug trials [20–23]. Therefore, we 
need to await ongoing prospective implementation tri-
als validating the clinical impact of REGS assignment in 
clinical resistant haematological malignancies, before 
introducing our “second generation” companion diagnos-
tics for malignant B cell diseases. However, the present 
case illustrates our research strategy for implementation 
of individualized care focused on patients with relapse or 
progression. The specific challenges in this area are the 
unexplained molecular drug resistance and the undocu-
mented use of drug combinations transferred from the 
“one size fits all” approach. Key to address this challenge 
is an understanding of the molecular/genetic profiles 
of each tumour such that we can tailor therapy appro-
priately, generate improved and evidence based clinical 
outcomes, and make the most efficient use of healthcare 
resources. Predictive companion diagnostics will iden-
tify multidrug resistant patients that will be extensively 
characterized and screened for specific pathway and/or 
Table 3 Probability of  resistance and  predicted R-class 
from http://www.Hemaclass.org
The probability of resistance towards cyclophosphamide (C), doxorubicin, (H), 
vincristine (O), and rituximab (R) determined by applying the REGS classification 
(Dybkaer et al. [18] and Laursen et al. [19] in preparation) onto .CEL files from 
Affymetrix U133plus2.0 arrays of the indicated samples through http://www.
hemaclass.org. A probability close to 1 predicts resistance, whereas a value close 
to 0, predicts sensitivity to the indicated drug
NC not classified




Probability of BAGS 0.595 0.363
BAGS class Centrocyte Memory
Probability of ABC 1.19E + 09 1.09E − 01
ABC‑GCB‑NC class GCB NC
Probability of R 0.034 0.049
R class Sensitive Sensitive
Probability of C 0.662 0.225
C class Resistant Sensitive
Probability of H 0.963 0.041
H class Resistant Sensitive
Probability of O 0.750 0.639
O class Resistant Resistant
Probability of Dex 0.023 0.037
Dex class Resistant Resistant
Probability combined 0.993 0.022
Combined class Resistant Sensitive
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mutations, attempting to validate target therapy by small 
and limited number of patients [56].
Conclusions
The present case of primary tFL was treated with con-
ventional R-CHOP and suffered from severe side effects 
but obtained a 6  months remission. However, she 
relapsed after 6 months and accepted palliation with 
rituximab and chlorambucil for 6 months. Unexpectedly, 
she obtained a continuous complete remission, at pre-
sent >9 years after primary diagnosis.
The retrospective analysis of the tumor tissue, docu-
mented the following key points:
  • Genomic sequencing, CNV and gene expression 
defined a branched evolution of the two independ-
ent lymphomas, most likely transformed from an 
unknown lymphoma in situ.
  • Classification for drug specific sensitivity and resist-
ance propose the targeted anti-CD20 antibody ther-
apy with the curative potential in the present case.
Together this case foresees a paradigm shift in the clini-
cal treatment culture for relapsed patients with haema-
tological malignancies—toward “personalised medicine” 
and “precision medicine” that need individual molecular 
work out [49–53].
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Additional file 1. Diagnostic image examinations of the patient case. A) 
The computed tomography (CT) from the primary lymphoma diag‑
nosis showed retroperitoneal bulk tumor and bilateral hydronephrosis 
(July 2007). B) A PET/CT was performed after six cycles of R‑CHOP and 
identified a large abdominal residual tumor without FDG (January 2008). 
C) A routine scan was performed after three months of follow‑up and 
confirmed continues remission (March 2008). D) A control scan was per‑
formed six months after therapy showing FDG accumulation in the retro‑
peritoneal residual tumor as well as a palpable cervical tumor (July 2008). 
After four cycles of rituximab and continues chlorambucil treatment (total 
6 months) a status scan was performed and showed a marked reduc‑
tion of FDG‑uptake in the abdominal bulk tumor (November 2008 ‑ data 
not shown), and repeated as illustrated in E) consistent with continuous 
complete remission (July 2010) according to the revised response criteria 
for malignant lymphoma. The superficial process at abdomen in E) was a 
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deposited at the GEO website under GSE86622. In total, U133 plus 2.0 
arrays were performed on 41 DLBCL, 2 tFL and 7 FL patient samples and 3 
SNP6.0 arrays were performed on the saliva, primary and relapse tumors 
on the patient case. Clinical data are registered in the National Clinical 
Quality Database for Malignant Lymphoma (http://www.lymphoma.dk).
lymphoma; FL: follicular lymphoma; SNP: single‑nucleotide polymorphism; 
INDEL: insertion or the deletion of bases in the DNA; CNV: copy number varia‑
tion; COO: cell of origin; NHL: non Hodgkin lymphoma.
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